{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T23:55:26Z","timestamp":1790034926188,"version":"4.0.1"},"reference-count":51,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007144","name":"University of Houston","doi-asserted-by":"publisher","award":["730"],"award-info":[{"award-number":["730"]}],"id":[{"id":"10.13039\/100007144","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Inhibition of the renin\u2013angiotensin system (RAS) may influence gut microbial composition and blood pressure, yet current evidence remains limited. This review examines how angiotensin-converting enzyme inhibitors (ACEis) and angiotensin receptor blockers (ARBs) modify gut microbiome composition, function, and blood pressure regulation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a systematic search of MEDLINE and EMBASE from inception to September 2025 using terms including \u201chuman,\u201d \u201crat,\u201d \u201cangiotensin converting enzyme inhibitor,\u201d \u201cangiotensin receptor blocker,\u201d and \u201cgut microbiome.\u201d Eligible studies were required to report changes in microbiome diversity, bacterial composition, or short-chain fatty acids (SCFAs) associated with ACEi\/ARB treatment across animal or human models. Data extraction and risk of bias assessments were performed independently by multiple reviewers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      After deduplication, 642 retrieved articles were filtered and nine met inclusion criteria (eight in rodent models, one human study). ACEi\/ARB administration in animals was associated with increased microbial diversity, restoration of intestinal oxygen balance, and enrichment of SCFA-producing anaerobic genera such as\n                      <jats:italic>Bifidobacterium<\/jats:italic>\n                      ,\n                      <jats:italic>Bacteroides<\/jats:italic>\n                      ,\n                      <jats:italic>Blautia<\/jats:italic>\n                      , and\n                      <jats:italic>Akkermansia<\/jats:italic>\n                      . In the human study, ACEi\/ARB use did not significantly alter microbial diversity, but decreased populations of facultative aerobic pathogens including\n                      <jats:italic>Staphylococcus<\/jats:italic>\n                      and\n                      <jats:italic>Enterobacterales<\/jats:italic>\n                      . Functionally, prolonged RAS inhibition elevated levels of acetate, propionate, and butyrate, and enhanced gut barrier integrity while attenuating inflammatory signaling. The human study was found to have a moderate risk of bias.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>ACEi and ARB therapies appear to reshape gut microbiome structure and metabolic function, promoting SCFA-producer expansion, improved gut barrier integrity, and modulation of microbial taxa linked to inflammation and hypertension. However, human data is limited, and further transitional research is needed to confirm these findings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2025.1685424","type":"journal-article","created":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T04:12:54Z","timestamp":1761192774000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Angiotensin converting enzyme inhibitors and angiotensin receptor blockers impact on the gut microbiome: a systematic review"],"prefix":"10.3389","volume":"16","author":[{"given":"Elisabeth M.","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulwhab","family":"Shremo Msdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vy N.","family":"Quach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selena Q.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Quach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhee","family":"Jo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taryn A.","family":"Eubank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin W.","family":"Garey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Rosario","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e93","DOI":"10.1161\/CIR.0000000000001123","article-title":"Heart disease and stroke statistics-2023 update: A report from the american heart association","volume":"147","author":"Tsao","year":"2023","journal-title":"Circulation"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2019.3773","article-title":"Population-attributable risk for cardiovascular disease associated with hypertension in black adults","volume":"4","author":"Clark","year":"2019","journal-title":"JAMA Cardiol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2017.1421","article-title":"Systolic blood pressure reduction and risk of cardiovascular disease and mortality: A systematic review and network meta-analysis","volume":"2","author":"Bundy","year":"2017","journal-title":"JAMA Cardiol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-022-00654-0","article-title":"The gut microbiome and hypertension","volume":"19","author":"O\u2019Donnell","year":"2023","journal-title":"Nat Rev Nephrol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s40168-016-0222-x","article-title":"Gut microbiota dysbiosis contributes to the development of hypertension","volume":"5","author":"Li","year":"2017","journal-title":"Microbiome"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa704","article-title":"Associations between gut microbiota, faecal short-chain fatty acids, and blood pressure across ethnic groups: the HELIUS study","volume":"41","author":"Verhaar","year":"2020","journal-title":"Eur Heart J"},{"key":"B7","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1152\/physiolgenomics.00081.2016","article-title":"Alterations in the gut microbiota can elicit hypertension in rats","volume":"49","author":"Adnan","year":"2017","journal-title":"Physiol Genomics"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00099.2021","article-title":"Gut microbiota and renin-angiotensin system: a complex interplay at local and systemic levels","volume":"321","author":"Jaworska","year":"2021","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijfoodmicro.2013.09.002","article-title":"Novel probiotic-fermented milk with angiotensin I-converting enzyme inhibitory peptides produced by Bifidobacterium bifidum MF 20\/5","volume":"167","author":"Gonzalez-Gonzalez","year":"2013","journal-title":"Int J Food Microbiol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/nature24628","article-title":"Salt-responsive gut commensal modulates TH17 axis and disease","volume":"551","author":"Wilck","year":"2017","journal-title":"Nature"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.122.18558","article-title":"Short-chain fatty acid receptors and blood pressure regulation: council on hypertension mid-career award for research excellence 2021","volume":"79","author":"Xu","year":"2022","journal-title":"Hypertension"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.2008.01981.x","article-title":"Renin-angiotensin system revisited","volume":"264","author":"Fyhrquist","year":"2008","journal-title":"J Intern Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2011.04971.x","article-title":"Review article: the pathophysiological roles of the renin-angiotensin system in the gastrointestinal tract","volume":"35","author":"Garg","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1042\/CS20180087","article-title":"Imbalance of gut microbiome and intestinal epithelial barrier dysfunction in patients with high blood pressure","volume":"132","author":"Kim","year":"2018","journal-title":"Clin Sci Lond Engl 1979"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1042\/CS20220904","article-title":"Restoration of the gut barrier integrity and restructuring of the gut microbiome in aging by angiotensin-(1-7)","volume":"137","author":"Chittimalli","year":"2023","journal-title":"Clin Sci Lond Engl 1979"},{"key":"B16","doi-asserted-by":"publisher","first-page":"71(6)","DOI":"10.1161\/HYP.0000000000000065","article-title":"ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: A report of the american college of cardiology\/american heart association task force on clinical practice guidelines","volume":"2018","author":"Whelton","year":"2017","journal-title":"Hypertension"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2019.109040","article-title":"Candesartan attenuates hypertension-associated pathophysiological alterations in the gut","volume":"116","author":"Wu","year":"2019","journal-title":"BioMed Pharmacother Biomed Pharmacother"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/bph.14965","article-title":"Changes to the gut microbiota induced by losartan contributes to its antihypertensive effects","volume":"177","author":"Robles-Vera","year":"2020","journal-title":"Br J Pharmacol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"B20","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan-a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-14-43","article-title":"SYRCLE\u2019s risk of bias tool for animal studies","volume":"14","author":"Hooijmans","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105724","article-title":"Telmisartan induces a specific gut microbiota signature which may mediate its antiobesity effect","volume":"170","author":"Beckmann","year":"2021","journal-title":"Pharmacol Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1096\/fasebj.2018.32.1_supplement.582.7","article-title":"Short-term captopril treatment causes persistently decreased blood pressure associated with long-lasting shifts in gut microbiota and improvement in gut pathology","volume":"32","author":"Yang","year":"2018","journal-title":"FASEB J"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23116060","article-title":"Enalapril diminishes the diabetes-induced changes in intestinal morphology, intestinal RAS and blood SCFA concentration in rats","volume":"23","author":"Jaworska","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.26355\/eurrev_202107_26247","article-title":"Research on the improvement of oxidative stress in rats with high-altitude pulmonary hypertension through the participation of irbesartan in regulating intestinal flora","volume":"25","author":"Nijiati","year":"2021","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1096\/fasebj.2021.35.S1.01524","article-title":"Gut microbiota modulate the efficacy of angiotensin-converting enzyme inhibitor captopril","volume":"35","author":"Kyoung","year":"2021","journal-title":"FASEB J"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.778072","article-title":"Effects of irbesartan and amlodipine besylate tablets on the intestinal microflora of rats with hypertensive renal damage","volume":"12","author":"Yu","year":"2021","journal-title":"Front Pharmacol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3390\/molecules28020612","article-title":"Effects of losartan, atorvastatin, and aspirin on blood pressure and gut microbiota in spontaneously hypertensive rats","volume":"28","author":"Dong","year":"2023","journal-title":"Mol Basel Switz"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.861829","article-title":"Antihypertensive therapy by ACEI\/ARB is associated with intestinal flora alterations and metabolomic profiles in hypertensive patients","volume":"10","author":"Dong","year":"2022","journal-title":"Front Cell Dev Biol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/s41440-021-00796-x","article-title":"Hypotensive effect of captopril on deoxycorticosterone acetate-salt-induced hypertensive rat is associated with gut microbiota alteration","volume":"45","author":"Wu","year":"2022","journal-title":"Hypertens Res Off J Jpn Soc Hypertens"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1177\/15593258211011342","article-title":"An insight into intestinal microbiota of spontaneously hypertensive rats after valsartan administration","volume":"19","author":"Qi","year":"2021","journal-title":"Dose-Response Publ Int Hormesis Soc"},{"key":"B33","doi-asserted-by":"publisher","first-page":"e010721","DOI":"10.1161\/JAHA.118.010721","article-title":"Sustained captopril-induced reduction in blood pressure is associated with alterations in gut-brain axis in the spontaneously hypertensive rat","volume":"8","author":"Yang","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000003613","article-title":"Lactobacillus induced by irbesartan on spontaneously hypertensive rat contribute to its antihypertensive effect","volume":"42","author":"Xiong","year":"2024","journal-title":"J Hypertens"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1111\/bph.16410","article-title":"Differing contributions of the gut microbiota to the blood pressure lowering effects induced by first-line antihypertensive drugs","volume":"181","author":"Gonz\u00e1lez-Correa","year":"2024","journal-title":"Br J Pharmacol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1007\/s11906-022-01216-2","article-title":"How dietary fibre, acting via the gut microbiome, lowers blood pressure","volume":"24","author":"Xu","year":"2022","journal-title":"Curr Hypertens Rep"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2020.00973","article-title":"An overview on fecal branched short-chain fatty acids along human life and as related with body mass index: associated dietary and anthropometric factors","volume":"11","author":"Rios-Covian","year":"2020","journal-title":"Front Microbiol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(90)91088-n","article-title":"Increased colonic mucosal angiotensin I and II concentrations in Crohn\u2019s colitis","volume":"98","author":"Jaszewski","year":"1990","journal-title":"Gastroenterology"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1111\/bcpt.13624","article-title":"Renin\u2013angiotensin system in intestinal inflammation\u2014Angiotensin inhibitors to treat inflammatory bowel diseases","volume":"129","author":"Salmenkari","year":"2021","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/s41440-023-01384-x","article-title":"Association between the gut microbiome and the renin-angiotensin-aldosterone system: a possible link via the activation of the immune system","volume":"46","author":"Gotoh","year":"2023","journal-title":"Hypertens Res Off J Jpn Soc Hypertens"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.115.05315","article-title":"Gut dysbiosis is linked to hypertension","volume":"65","author":"Yang","year":"2015","journal-title":"Hypertens Dallas Tex 1979"},{"key":"B42","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s13099-024-00635-7","article-title":"The influence of Akkermansia muciniphila on intestinal barrier function","volume":"16","author":"Mo","year":"2024","journal-title":"Gut Pathog"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2016.00979","article-title":"Bifidobacteria and butyrate-producing colon bacteria: importance and strategies for their stimulation in the human gut","volume":"7","author":"Rivi\u00e8re","year":"2016","journal-title":"Front Microbiol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.freeradbiomed.2016.09.022","article-title":"Oxygen as a driver of gut dysbiosis","volume":"105","author":"Rivera-Ch\u00e1vez","year":"2017","journal-title":"Free Radic Biol Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3390\/nu11122908","article-title":"Hypertension programmed by perinatal high-fat diet: effect of maternal gut microbiota-targeted therapy","volume":"11","author":"Hsu","year":"2019","journal-title":"Nutrients"},{"key":"B46","article-title":"Role of the vasodilator peptide angiotensin-(1-7) in cardiovascular drug therapy","volume":"3","author":"Schindler","year":"2007","journal-title":"Vasc Health Risk Manage"},{"key":"B47","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s40264-014-0239-7","article-title":"The comparative efficacy and safety of the angiotensin receptor blockers in the management of hypertension and other cardiovascular diseases","volume":"38","author":"Abraham","year":"2015","journal-title":"Drug Saf"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.30.1.42","article-title":"Angiotensin II type 1 (AT1) receptor\u2013mediated accumulation of angiotensin II in tissues and its intracellular half-life","volume":"30","author":"van Kats","year":"1997","journal-title":"In Vivo Hyperten"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26010113","article-title":"Direct vascular effects of angiotensin II (A systematic short review)","volume":"26","author":"N\u00e1dasy","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvae062","article-title":"Influence of angiotensin II on the gut microbiome: modest effects in comparison to experimental factors","volume":"120","author":"Muralitharan R","year":"2024","journal-title":"Cardiovasc Res"},{"key":"B51","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1007\/s11906-021-01157-2","article-title":"The role of gut microbiota in hypertension pathogenesis and the efficacy of antihypertensive drugs","volume":"23","author":"Xiong","year":"2021","journal-title":"Curr Hypertens Rep"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1685424\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T04:12:55Z","timestamp":1761192775000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1685424\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,23]]},"references-count":51,"alternative-id":["10.3389\/fendo.2025.1685424"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1685424","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,23]]},"article-number":"1685424"}}